Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 29,595 Shares

Posted by Francis Steltz on Jun 4th, 2026

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 29,595 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $0.45, for a total value of $13,317.75. Following the completion of the sale, the director directly owned 512,525 shares of the company’s stock, valued at $230,636.25. The trade was a 5.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

On Wednesday, June 3rd, Luke Evnin sold 29,749 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total value of $12,494.58.
On Monday, June 1st, Luke Evnin sold 80,459 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total value of $37,815.73.
On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $14,650.20.
On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.46, for a total value of $12,741.08.
On Wednesday, May 27th, Luke Evnin sold 80,852 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.48, for a total value of $38,808.96.
On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total value of $31,936.50.
On Friday, May 22nd, Luke Evnin sold 87,425 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $39,341.25.
On Thursday, May 21st, Luke Evnin sold 36,387 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total value of $15,282.54.
On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.43, for a total value of $36,934.85.
On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $28,336.50.

Werewolf Therapeutics Stock Performance

Werewolf Therapeutics stock opened at $0.42 on Thursday. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.40 and a fifty-two week high of $2.38. The company has a market capitalization of $20.53 million, a P/E ratio of -0.34 and a beta of 0.29. The stock has a 50-day simple moving average of $0.72 and a 200-day simple moving average of $0.74.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. As a group, analysts forecast that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current year.

Institutional Trading of Werewolf Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in HOWL. Regal Investment Advisors LLC increased its position in Werewolf Therapeutics by 93.3% during the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after purchasing an additional 25,389 shares during the period. Vontobel Holding Ltd. increased its position in Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after purchasing an additional 24,003 shares during the period. Qube Research & Technologies Ltd acquired a new position in Werewolf Therapeutics during the 2nd quarter worth approximately $48,000. AQR Capital Management LLC acquired a new position in Werewolf Therapeutics during the 1st quarter worth approximately $79,000. Finally, Bridgeway Capital Management LLC increased its position in Werewolf Therapeutics by 157.7% during the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after purchasing an additional 62,414 shares during the period. 64.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on HOWL. Wall Street Zen downgraded Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $3.75.

Read Our Latest Report on Werewolf Therapeutics

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.